Gibson is a board-certified clinical biochemical geneticist, and has studied a number of Mendelian disorders of metabolism for the better part of 30 years. His research focus includes understanding the pathophysiology of selected disorders, and developing novel pre-clinical treatment approaches with translational relevance. His laboratory employs pharmacological, cellular and dietary treatment approaches in disorders such as succinic semialdehyde dehydrogenase deficiency, phenylketonuria, maple syrup urine disease, galactosemia and transaldolase deficiency, a defect of the pentose phosphate pathway. His training is in protein chemistry, molecular and neurobiology, neuropharmacology and genetics, and various analytical methodologies. His laboratory is actively interested in hepatic biology and novel approaches to liver regeneration. Gibson is the chair of the Medical and Scientific Advisory Board of the SSADH Association, which represents children and families affected by Succinic Semialdehyde Dehydrogenase Deficiency (SSADH). Much of his research is focused on this disease.